Literature DB >> 24553520

Hemostatic resuscitation is neither hemostatic nor resuscitative in trauma hemorrhage.

Sirat Khan1, Karim Brohi, Manik Chana, Imran Raza, Simon Stanworth, Christine Gaarder, Ross Davenport.   

Abstract

BACKGROUND: Trauma hemorrhage continues to carry a high mortality rate despite changes in modern practice. Traditional approaches to the massively bleeding patient have been shown to result in persistent coagulopathy, bleeding, and poor outcomes. Hemostatic (or damage control) resuscitation developed from the discovery of acute traumatic coagulopathy and increased recognition of the negative consequences of dilutional coagulopathy. These strategies concentrate on early delivery of coagulation therapy combined with permissive hypotension. The efficacy of hemostatic resuscitation in correcting coagulopathy and restoring tissue perfusion during acute hemorrhage has not been studied.
METHODS: This is a prospective cohort study of ROTEM and lactate measurements taken from trauma patients recruited to the multicenter Activation of Coagulation and Inflammation in Trauma (ACIT) study. A blood sample is taken on arrival and during the acute bleeding phase after administration of every 4 U of packed red blood cells (PRBCs), up to 12 U. The quantity of blood products administered within each interval is recorded.
RESULTS: Of the 106 study patients receiving at least 4 U of PRBC, 27 received 8 U to 11 U of PRBC and 31 received more than 12 U of PRBC. Average admission lactate was 6.2 mEq/L. Patients with high lactate (≥5 mEq/L) on admission did not clear lactate until hemorrhage control was achieved, and no further PRBC units were required. On admission, 43% of the patients were coagulopathic (clot amplitude at 5 minutes ≤ 35 mm). This increased to 49% by PRBC 4; 62% by PRBC 8 and 68% at PRBC 12. The average fresh frozen plasma/PRBC ratio between intervals was 0.5 for 0 U to 4 U of PRBC, 0.9 for 5 U to 8 U of PRBC, 0.7 for 9 U to 12 U of PRBC. There was no improvement in any ROTEM parameter during ongoing bleeding.
CONCLUSION: While hemostatic resuscitation offers several advantages over historical strategies, it still does not achieve correction of hypoperfusion or coagulopathy during the acute phase of trauma hemorrhage. Significant opportunities still exist to improve management and improve outcomes for bleeding trauma patients. LEVEL OF EVIDENCE: Epidemiologic study, level III.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24553520     DOI: 10.1097/TA.0000000000000146

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  43 in total

1.  Hemostatic resuscitation is neither hemostatic nor resuscitative in trauma hemorrhage-But did they in fact test the effect of hemostatic resuscitation?

Authors:  Jakob Stensballe; John B Holcomb
Journal:  J Trauma Acute Care Surg       Date:  2015-06       Impact factor: 3.313

Review 2.  The research agenda for trauma critical care.

Authors:  Karim Asehnoune; Zsolt Balogh; Giuseppe Citerio; Andre Cap; Timothy Billiar; Nino Stocchetti; Mitchell J Cohen; Paolo Pelosi; Nicola Curry; Christine Gaarder; Russell Gruen; John Holcomb; Beverley J Hunt; Nicole P Juffermans; Mark Maegele; Mark Midwinter; Frederick A Moore; Michael O'Dwyer; Jean-François Pittet; Herbert Schöchl; Martin Schreiber; Philip C Spinella; Simon Stanworth; Robert Winfield; Karim Brohi
Journal:  Intensive Care Med       Date:  2017-07-29       Impact factor: 17.440

3.  A regional massive hemorrhage protocol developed through a modified Delphi technique.

Authors:  Jeannie L Callum; Calvin H Yeh; Andrew Petrosoniak; Mark J McVey; Stephanie Cope; Troy Thompson; Victoria Chin; Keyvan Karkouti; Avery B Nathens; Kimmo Murto; Suzanne Beno; Jacob Pendergrast; Andrew McDonald; Russell MacDonald; Neill K J Adhikari; Asim Alam; Donald Arnold; Lee Barratt; Andrew Beckett; Sue Brenneman; Hina Razzaq Chaudhry; Allison Collins; Margaret Harvey; Jacinthe Lampron; Clarita Margarido; Amanda McFarlan; Barto Nascimento; Wendy Owens; Menaka Pai; Sandro Rizoli; Theodora Ruijs; Robert Skeate; Teresa Skelton; Michelle Sholzberg; Kelly Syer; Jami-Lynn Viveiros; Josee Theriault; Alan Tinmouth; Rardi Van Heest; Susan White; Michelle Zeller; Katerina Pavenski
Journal:  CMAJ Open       Date:  2019-09-03

Review 4.  [Modern coagulation management in bleeding trauma patients : Point-of-care guided administration of coagulation factor concentrates and hemostatic agents].

Authors:  Marc Maegele
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-08-28       Impact factor: 0.840

5.  Prediction models to advance individualized resuscitation in trauma hemorrhage and acute traumatic coagulopathy (ATC): even the longest journey starts with first steps-Lao-Tzu (Chinese philosopher).

Authors:  Marc Maegele
Journal:  Ann Transl Med       Date:  2017-12

6.  Activated Protein C Drives the Hyperfibrinolysis of Acute Traumatic Coagulopathy.

Authors:  Ross A Davenport; Maria Guerreiro; Daniel Frith; Claire Rourke; Sean Platton; Mitchell Cohen; Rupert Pearse; Chris Thiemermann; Karim Brohi
Journal:  Anesthesiology       Date:  2017-01       Impact factor: 7.892

Review 7.  [Viscoelasticity-based treatment of bleeding injuries].

Authors:  Marc Maegele; Michael Caspers; Herbert Schöchl
Journal:  Unfallchirurg       Date:  2017-09       Impact factor: 1.000

8.  [Early viscoelasticity-based coagulation therapy for severely injured bleeding patients: Report of the consensus group on the consensus conference 2014 for formulation of S2k guidelines].

Authors:  M Maegele; K Inaba; S Rizoli; P Veigas; J Callum; R Davenport; M Fröhlich; J Hess
Journal:  Anaesthesist       Date:  2015-10       Impact factor: 1.041

9.  A Fibrin Cross-linking Polymer Enhances Clot Formation Similar to Factor Concentrates and Tranexamic Acid in an in vitro Model of Coagulopathy.

Authors:  Leslie W Chan; Nathan J White; Suzie H Pun
Journal:  ACS Biomater Sci Eng       Date:  2016-01-28

Review 10.  [Fluid resuscitation in hemorrhage].

Authors:  M Roessler; K Bode; M Bauer
Journal:  Anaesthesist       Date:  2014-10       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.